MaxCyte Partners with Adicet Bio to License Electroporation Technology

MaxCyte (NASDAQ: MXCT) announced on Monday that it has entered into a strategic licensing agreement with Adicet Bio. This partnership grants Adicet Bio non-exclusive rights to utilize MaxCyte's innovative Flow Electroporation technology and ExPERT platform for research, clinical, and commercial purposes. In exchange, MaxCyte will receive licensing fees and revenue shares related to the program. Following the announcement, MXCT shares increased by 2.45% in premarket trading, reaching $2.09. Source: Press Release